![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Reasons for Treatment Discontinuation Among Hepatitis C Patients Treated in Clinical Practice
|
|
|
Reported by Jules Levin
APASL 2013 Singapore June 6-10
Ulcickas Yood MU,1 Sapra S,2 Oliveria SA,1 Casso D,1 Fu A-C,3 L'Italien GJ2
1EpiSource, LLC, Newton, MA; 2Bristol-Myers Squibb, Plainsboro, NJ; 3HealthCore, Wilmington, DE
BACKGROUND
Previous investigation has indicated low viral suppression in patients who discontinue treatment with peginterferon alfa-2a or alfa-2b (alfa) and ribavirin (RBV) for chronic hepatitis C
The objective of the current analysis was to investigate reasons for treatment discontinuation in a clinical setting of patients treated with alfa/RBV, which either together or with newly approved antivirals is the current treatment for hepatitis C
![APASL1.gif](../images/061713/061713-3/APASL1.gif)
![APASL2.gif](../images/061713/061713-3/APASL2.gif)
![APASL3.gif](../images/061713/061713-3/APASL3.gif)
![APASL4.gif](../images/061713/061713-3/APASL4.gif)
![APASL5.gif](../images/061713/061713-3/APASL5.gif)
![APASL6.gif](../images/061713/061713-3/APASL6.gif)
![APASL7.gif](../images/061713/061713-3/APASL7.gif)
![APASL8.gif](../images/061713/061713-3/APASL8.gif)
![APASL9.gif](../images/061713/061713-3/APASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|